Cn /En

News Center

——

Company news

Industry news

Introduction to the in vivo tumor experimental platform of InnoModels Biotechnology

Author:

InnoModels

Release time:

2024-10-08

In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is leading the forefront of tumor and tumor immunotherapy research with its unique in vivo tumor experimental platform, which is like a bright star. The platform not only integrates the most advanced technologies and experimental methods, but also devotes itself to providing a new generation of experimental animal models close to the clinic.
Leading Innovation: The Birth of the In Vivo Tumor Experiment Platform
InnoModels' In Vivo Tumor Platform is a comprehensive tool designed specifically for preclinical research in oncology and tumor immunotherapy. The platform incorporates a variety of advanced technologies and experimental methods, such as CDX (cell-derived xenograft) model, iHuPDX (humanized patient-derived tumor xenograft) model, brain in situ model, and many other in situ models, covering a wide range of tumor types and complex in vivo environment simulations. These models not only ensure the accuracy of experimental results, but also greatly improve the efficiency and depth of research.

The Perfect Fusion of Stability and Efficacy: iHuPDX Models
The iHuPDX model stands out among the many models from InnoModels Biotechnology for its unparalleled stability and growth rate. The model ensures homogenization of samples between batches with the help of primary cell inoculation technology, thus maintaining a high degree of consistency in growth rate and biological characteristics. This stability provides a reliable guarantee for long-term research and makes the experimental results more credible. Meanwhile, the iHuPDX model achieves uniform growth at the early stage, and the efficacy experiments are carried out in the P2-P5 generation, which avoids changes in properties and model wastage caused by multiple passages, and significantly reduces the cost of the experiment.
Bridge to personalized treatment: PBMC-OncVax tumor vaccine model
In addition to the iHuPDX model, InnoModels Biotechnology has also launched the PBMC-OncVax tumor vaccine model, an innovation that has attracted widespread attention in the field of cancer immunotherapy. The model uses patients' own peripheral blood mononuclear cells (PBMCs) and provides an important tool for personalized treatment and vaccine research by simulating the individual immune system response to tumors.The PBMC-OncVax model not only improves the targeting of vaccines, but also enhances the effectiveness of immunotherapy and provides scientists with the possibility of comprehensively evaluating multiple immune responses.
Comprehensive Services and Support
InnoModels' in vivo tumor experimental platform not only possesses advanced technologies and models, but also provides comprehensive services and support. The platform has a team of experienced experts and PhDs who are dedicated to providing scientific support for each project, from experimental design, data interpretation to problem solving, to assist researchers in all aspects of their research work. In addition, the platform maintains thorough and traceable experimental records to ensure data integrity and regulatory compliance, ensuring the safety of researchers' studies.
Conclusion
With its unique advantages and innovative spirit, the InnoModels Biotechnology in vivo tumor experimental platform plays a crucial role in the field of cancer research and treatment. The platform not only promotes the in-depth development of oncology and tumor immunotherapy research, but also provides strong support for personalized medicine and new drug development. In the future, InnoModels Biotechnology will continue to stand at the forefront of scientific innovation, continuously optimize and improve the platform technology, provide more comprehensive and efficient services to researchers, and jointly create a new chapter in cancer treatment.

In Vitro Killing Experiment Platform of InnoModels Biotechnology

In Vitro Killing Experimental Platform from InnoModels Biotechnology

In Vitro Killing Experiment Platform of InnoModels Biotechnology

In Vitro Killing Experimental Platform from InnoModels Biotechnology

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License